Answers are grounded in this paper and cite their sources.
Novel drugs and continuous therapy have improved outcomes in patients with multiple myeloma (MM); however, current therapies are largely non-curative with diminishing durations of response with subsequent therapies. Cellular therapies including chimeric antigen receptor T (CAR-T) cells have started to illustrate deeper and longer durations of relapse in the relapsed/refractory population. Current research seeks to expand on the durability of response, novel combinations, and targets, as well as the timing of CAR-T cells in the treatment schema. This review summarizes the updates in cellular therapy for MM.
No takes yet. Share an insight, caveat, or question.
Gregory et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: